Hereditary Spastic Paraplegia Protein Spartin Is an FK506-Binding Protein Identified by mRNA Display  by Tokunaga, Mayuko et al.
Chemistry & Biology
ArticleHereditary Spastic Paraplegia Protein Spartin Is
an FK506-Binding Protein Identified by mRNA Display
Mayuko Tokunaga,1 Hirokazu Shiheido,1 Ichigo Hayakawa,1 Akiko Utsumi,1 Hideaki Takashima,1 Nobuhide Doi,1,*
Kenichi Horisawa,1 Yuko Sakuma-Yonemura,1 Noriko Tabata,1 and Hiroshi Yanagawa1
1Department of Biosciences and Informatics, Keio University, 3-14-1 Hiyoshi, Kohoku-ku, Yokohama 223-8522, Japan
*Correspondence: doi@bio.keio.ac.jp
http://dx.doi.org/10.1016/j.chembiol.2013.05.011SUMMARY
Here, we used mRNA display to search for proteins
that bind to FK506, a potent immunosuppressant
drug, and identified spartin, a hereditary spastic
paraplegia protein, from a human brain cDNA library.
We demonstrated that FK506 binds to the C-terminal
region of spartin and thereby inhibits the interaction
of spartin with TIP47, one of the lipid droplet-associ-
ated proteins. We further confirmed that FK506
inhibits localization of spartin and its binder, an E3
ubiquitin ligase AIP4, in lipid droplets and increases
the protein level of ADRP (adipose differentiation-
related protein), which is a regulator of lipid homeo-
stasis. These results strongly suggest that FK506
suppresses the proteasomal degradation of ADRP,
a substrate of AIP4, by inhibiting the spartin-TIP47
interaction and thereby blocking the localization of
spartin and AIP4 in lipid droplets.
INTRODUCTION
FK506 (tacrolimus) is a potent immunosuppressant drug used for
preventing graft rejection in organ or bone marrow transplanta-
tion and for treating autoimmune diseases, including atopic
dermatitis and rheumatoid arthritis (Miyata et al., 2005). FK506
is a 23-membered macrolide lactone that was isolated from
Streptomyces tsukubaensis in 1984 (Tanaka et al., 1987). The
molecularmechanismof its immunosuppressive actionwas clar-
ified in 1991 (Liu et al., 1991; Schreiber, 1991). In a normal
immune response, calcineurin dephosphorylates NFAT (nuclear
factor of activated T cells), allowing NFAT to be transferred into
the nucleus, where it enhances the transcription of several
genes, including the cytokine interleukin-2 that serves as a mas-
ter regulator for activation of the immune system (Emmel et al.,
1989). Schreiber and colleagues found that FK506 binds to
FKBP12 (FK506 binding protein 12 kDa) and the FK506-
FKBP12 complex inhibits dephosphorylation of NFAT through
binding to calcineurin (Liu et al., 1991; Schreiber, 1991).
In this study, we aimed to discover FK506-binding proteins by
using mRNA display (Nemoto et al., 1997; Roberts and Szostak,
1997). mRNA display is a method for construction of a library of
protein-mRNA conjugates in which each protein (phenotype) is
covalently linked to its encodingmRNA (genotype) through puro-Chemistry & Biology 20,mycin (Nemoto et al., 1997; Roberts and Szostak, 1997). After af-
finity selection based on the association of a bait (e.g., protein,
nucleic acid, and chemicals) with the protein portion of conju-
gates, the mRNA portion of selected molecules can be easily
amplified by RT-PCR and used for the next round of selection
and ultimately for sequence identification (Figure 1). So far,
mRNA display has been used for in vitro selection of proteins
that bind to various targets including proteins (Horisawa et al.,
2004; Miyamoto-Sato et al., 2005; Tamada et al., 2012), cis
DNA element (Tateyama et al., 2006), and small-molecular com-
pounds (Shiheido et al., 2012a, 2012b) from cDNA libraries.
Moreover, mRNA display has already been applied to selection
of FK506-binding proteins from a mixed cDNA library derived
from human liver, kidney, and bone marrow, but only the
FKBP12 gene was preferentially enriched during the PCR ampli-
fication and affinity selection steps (McPherson et al., 2002),
probably because FKBP12 is a small protein (12 kDa) with
high affinity for FK506 (Kd = 0.4 nM; Bierer et al., 1990). Here,
to prevent the preferential enrichment of FKBP12 gene, we elim-
inated short DNA fragments including FKBP12 gene by gel elec-
trophoresis in each round of mRNA display selection. Further-
more, we performed selection of a cDNA library derived from
human brain, because we were most interested in the neurotox-
icity of FK506 (Shou et al., 1998). Consequently, we identified
spartin, a hereditary spastic paraplegia (HSP) protein, which is
related to neural disease and disorder (Bakowska et al., 2008;
Manzini et al., 2010; Patel et al., 2002), as a FK506 binder and
characterized the effect of FK506 binding on spartin function.RESULTS
Spartin Interacts with FK506 through Its C-Terminal
Region
Affinity selection of FK506-binding proteins was performed using
FK506-biotin (Figure 2A) immobilized on streptavidin beads as
previously described (McPherson et al., 2002). After four rounds
of selection, we obtained a C-terminal fragment of SPG20 gene,
encoding spartin (433–584 amino acids; Figure 2B) as a distinct
positive clone. No point mutation was found in the fragment.
To determine whether spartin interacts with FK506 directly,
we performed in vitro pull-down assays of green fluorescent pro-
tein (GFP)-fused spartin using FK506-immobilized beads. As
expected, GFP-spartin bound to FK506, while GFP-SpartinDC,
in which amino acid residues 349–666 of spartin including a
putative FK506 binding region are deleted, did not (Figure 2C,
top). This result shows that the C-terminal region of spartin is935–942, July 25, 2013 ª2013 Elsevier Ltd All rights reserved 935
Figure 1. Schematic Representation of mRNA Display
(1) A cDNA library derived from human brain is transcribed and ligated with a
PEG-puromycin spacer. (2) The resulting mRNA template is in vitro translated
to form a library of protein-mRNA conjugates. (3) The library is incubated with
FK506-immobilized beads and unbound molecules are washed away. (4) The
bound molecules are eluted with proteinase K and their mRNA portion is
amplified by RT-PCR. The resulting DNA is size-fractionated and the larger
DNA fragments are used for the next round of selection. (5) After iterative
selection, the enriched DNA is analyzed by cloning and sequencing.
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formed a competitive pull-down assay in the presence of free
FK506: the amount of GFP-fused spartin bound to biotinylated
FK506 decreased with an increase in free FK506 concentration
(Figure 2C, bottom).
Next, we examined whether endogenous spartin binds to
FK506. We performed a pull-down assay of endogenous spartin
in total cell lysates using beads bearing FK506 or an FK506
analog (Dubowchik et al., 2000) named FKL that retains the
FKBP12-binding site (Figure 2A). The result showed that endog-
enous spartin binds not only to FK506, but also FKL (Figure 2D,
top). In addition, we confirmed that the binding of endogenous
spartin with bead-immobilized FK506 was completed with free
FK506 (Figure 2D, bottom).
Moreover, we performed a competitive ELISA capable of
quantifying FLAG-tagged spartin bound to immobilized FK506
in the presence of free FK506 or rapamycin (Figure 2A). The
amount of FLAG-spartin bound to immobilized FK506 decreased
with an increase in free FK506 or rapamycin concentration (Fig-
ure 2E). Because FK506, FKL, and rapamycin contain a common
‘‘FKBP12-binding structure’’ (a-keto proline amide linkage), the
C-terminal region of spartin also probably binds to the
FKBP12-binding portion of FK506.
Finally, we examined the affinity of His6-tagged spartin for bio-
tinylated FK506 with surface plasmon resonance (SPR) analysis
(Figure 2F). The measured Kd value was 0.1 mM: the affinity is
quite lower than that for FKBP12 (Kd = 0.4 nM) but enough to
achieve efficient enrichment within four rounds of mRNA-display
selection.
FK506 Inhibits Spartin Localization in Lipid Droplets
The C-terminal region of spartin is essential for localization in
lipid droplets (Eastman et al., 2009). Lipid droplets are cellular936 Chemistry & Biology 20, 935–942, July 25, 2013 ª2013 Elsevier Lorganelles that store neutral lipids, surrounded by a phospho-
lipid monolayer in which certain associated proteins are
embedded. The organelles play a central role in whole-body lipid
homeostasis (Digel et al., 2010). On the surface of lipid droplets,
spartin recruits HECT (homologous to the E6-AP carboxyl termi-
nus) E3 ubiquitin ligase AIP4 (atrophin-1-interacting protein 4)
through its N-terminal PPXY motif and thereby promotes
ubiquitination and proteasomal degradation of lipid droplet-
associated protein ADRP (adipose differentiation-related pro-
tein; Eastman et al., 2009; Edwards et al., 2009; Hooper et al.,
2010; Figure 3A).
First, we examined the effect of FK506 binding to the C-ter-
minal region of spartin on the localization of spartin and AIP4 in
lipid droplets. HeLa cells co-expressing HA-tagged spartin and
FLAG-tagged AIP4 were treated with 0–10 mM FK506 for 1 hr.
Immunofluorescent staining followed by fluorescence micro-
scopy showed that HA-spartin and FLAG-AIP4 were colocal-
ized in lipid droplets in most of the cells without FK506 treat-
ment. However, these proteins were colocalized in lipid
droplets in less than half of cells treated with FK506. The per-
centage of lipid droplets in which HA-spartin and FLAG-AIP4
were colocalized decreased from 85% to 24% with 1 mM
and to 14% with 10 mM FK506 (Figures 3B and 3C). We also
confirmed that FK506 does not affect the expression level of
either HA-spartin or FLAG-AIP4 (Figure 3D). These results sug-
gest that FK506 decreased the amount of spartin and AIP4
proteins localized in lipid droplets not through suppressing
protein expression, but by blocking the localization of the pro-
teins in lipid droplets in an FK506 concentration-dependent
manner.
Next, we examined whether FK506 inhibits the interaction
between spartin and TIP47 (tail interacting protein of 47 kDa),
one of the lipid droplet-associated proteins, because localiza-
tion of spartin in lipid droplets involves interaction with TIP47
through its C-terminal region (Eastman et al., 2009). HA-tagged
spartin and TIP47-GST fusion protein were co-expressed in
HeLa cells, and then the complex of HA-spartin and TIP47-
GST was purified with glutathione beads in the presence of
FK506. We found that the interaction between HA-spartin
and TIP47-GST was inhibited in a FK506 concentration-depen-
dent manner (Figure 3E). We also performed a competitive
ELISA and found that the amount of T7-tagged spartin bound
to immobilized TIP47-GST decreased with an increase in free
FK506 concentration (Figure 3F). This result indicates that
FK506 directly inhibits the interaction between spartin and
TIP47.
Finally, we examined whether FK506 inhibits AIP4-mediated
proteasomal degradation of ADRP because spartin is known to
act as an adaptor that recruits AIP4 to lipid droplets and in-
creases its enzymatic activity (Hooper et al., 2010). HeLa cells
were treated with or without 50 mg/ml cycloheximide, a protein
synthesis inhibitor, for 20 min and then treated with 0–20 mM
FK506 for 1 hr. As a result, the ADRP protein level was gradually
increased relative to when the FK506 concentration was gradu-
ally increased, both in the presence and absence of cyclohexi-
mide (Figure 4A), while FK506 did not change the ADRP mRNA
level (Figure 4B). Furthermore, FK506 did not affect the protein
level of spartin and TIP47 with or without cycloheximide (Figures
4C and 4D). These results strongly suggest that FK506td All rights reserved
Figure 2. FK506 Bound to the C-Terminal Region of Spartin
(A) The chemical structures of biotinylated FK506, rapamycin, and FKL, which is an FK506 analog that retains the FKBP12-binding site, are depicted. FK506 and
FKL were biotinylated through a linker placed outside the FKBP12-binding site.
(B) The domain structure of spartin protein and the mutated region of the SPG20 gene in patients with HSP are shown. Spartin harbors an N-terminal MIT
(microtubule interacting and trafficking) domain, a PPXYmotif forWWdomain recognition, and a lesswell-characterized plant-related senescence domain at its C
terminus. Patients with HSP have a two-base-pair deletion (364_365 delAT) or a single-base-pair deletion (1110 delA) in the spartin gene, resulting in a frameshift
andC-terminal truncation of spartin (Manzini et al., 2010; Patel et al., 2002). The C-terminal region (433–584 amino acids) of spartin (the FK506 binding region) was
selected by using mRNA display.
(C, top) Pull-down assays of GFP-fused spartin with FK506. HEK293T cells were transfected with a construct expressing GFP-spartin, GFP-SpartinDC
(a C-terminal deletion mutant of spartin, 1–348 amino acids) or GFP. After 48 hr, whole cell lysates were prepared and used for pull-down assays with FK506-
immobilized (+) or nonimmobilized () beads. Each fraction was separated with 8% SDS-PAGE, and the fluorescence of GFP was detected by using Molecular
Imager FX. A band, which shifted 10 kDa upward (markedwith an asterisk), presumably represents themonoubiquitinated form of spartin (Bakowska et al., 2007).
I, input; F, flow through; B, beads fraction. (Bottom) Competitive pull-down assays of GFP-fused spartin with FK506-immobilized beads in the presence of
0–100 mM free FK506.
(D, top) Pull-down assays of HeLa cell endogenous spartin with FK506 and FKL. Whole cell lysates of HeLa cells were prepared and pull-down assays were
performed. Each fraction was separated by 8% SDS-PAGE and bands were detected with western blot analysis with an antibody against spartin. (Bottom)
Competitive pull-down assays of HeLa cell endogenous spartin with FK506-immobilized beads were performed in the presence of 0–100 mM free FK506 as
described above. Mock: beads without any compound.
(E) FLAG-spartin was generated by in vitro translation, bound to biotinylated FK506 in the presence of various concentrations of free FK506 or rapamycin and
quantified with ELISA. Error bars represent SD.
(F) A representative biosensorgram of spartin binding on SA sensor chips with immobilized biotinylated-FK506 is shown. To determine the Kd values, three
different concentrations (509, 407, and 305 mM) of purified spartin with His6-tag were used. The SE for Kd is approximately ± 5%.
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Figure 3. FK506 Inhibited Localization of
Spartin and AIP4 in Lipid Droplets
(A) A hypothesis: FK506 binds to the C terminus of
spartin and inhibits its binding to lipid droplet-
associated protein TIP47. Thereby, it prevents
colocalization of spartin and AIP4 in lipid droplets
and the proteasomal degradation of ADRP. The
colors of these proteins refer to the fluorescence
colors in Figure 3B.
(B) Immunofluorescence staining using anti-HA-
tag (CF640, red) and anti-AIP4 (Alexa568, blue) of
HeLa cells transfected with HA-spartin and FLAG-
AIP4 genes and, after 24 hr, treated with 0–10 mM
FK506 for 1 hr. Lipid droplet staining with BOD-
IPY493/503 (green) is also shown. The samples
were observed under a fluorescence microscope.
Lipid droplets colocalized with HA-spartin and
FLAG-AIP4 are indicated by white arrowheads,
otherwise by a white arrow. Bar = 10 mm.
(C) Colocalization of HA-spartin and FLAG-AIP4 in
lipid droplets was scored for 40–90 lipid droplets in
each of three independent experiments. The ratio
under the indicated conditions is shown. Error
bars represent SD.
(D) Expression levels of HA-spartin and FLAG-
AIP4 in HeLa cells treated with 0–10 mM FK506
were analyzed with western blot analysis with
antibody against HA-tag and FLAG-tag, respec-
tively. b-Actin is shown to verify equal loading.
(E) GST pull-down assays in the presence of
0–20 mM FK506 using HA-spartin and TIP47-GST
co-expressed in HEK293T cells. Each fraction was
separated with 8% SDS-PAGE and then analyzed
with western blot analysis with an antibody against
HA-tag or GST. I, input; B, beads fraction.
(F) T7-tagged spartin was generated by in vitro
translation, bound to TIP47-GST in the presence
of various concentrations of free FK506, and
quantified with ELISA. Error bars represent SD.
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of AIP4, by blocking the localization of spartin in lipid droplets
and the enhancement of the ubiquitin ligase activity of AIP4.938 Chemistry & Biology 20, 935–942, July 25, 2013 ª2013 Elsevier Ltd All rights reservedDISCUSSION
There are several possible reasons why
spartin was successfully selected from
the human brain cDNA library, while in
the previous study only FKBP12 was
selected from human liver, kidney, and
bone marrow cDNA libraries by mRNA
display selection using identical FK506-
biotin as bait (McPherson et al., 2002).
One possibility is that spartin is highly ex-
pressed in human brain, but not in liver,
kidney, and bone marrow, and so would
be identified only when a human brain
cDNA library was used. However, this is
not the case, because the expression
levels in these organs are reported to be
similar to those in brain (Manzini et al.,
2010). Therefore, we thought that ouruse of DNA size fractionation was the reason for the apparent
discrepancy. Because the FK506-binding affinity of FKBP12
(Kd = 0.4 nM; Bierer et al., 1990) is quite higher than that of spartin
Figure 4. FK506 Inhibited Proteasomal Degradation of ADRP
(A, C, and D) Expression level of ADRP (A), spartin (C), and TIP47 (D) protein in
HeLa cells treated with (+) or without () cycloheximide, and then treated with
0–20 mM FK506 for 1 hr. The whole cell lysates were separated with 8%
SDS-PAGE and analyzed with western blot analysis with an antibody against
ADRP, spartin, and TIP47, respectively (top). The band intensity was quantified
and normalized with that of b-actin (bottom). Error bars represent SD.
(B) The amount of ADRPmRNA in HeLa cells treated with 0 or 20 mMFK506 for
1 hr. The total RNA was extracted and then amplified by RT-PCR with specific
primer for GAPDH or ADRP.
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affinity selection in the previous study (McPherson et al., 2002).
Because we eliminated DNA fragments shorter than 400 bp
with gel electrophoresis, the C-terminal fragment of the spartin
gene (433–584 amino acids; 450 bp) was selected, whereas
no FKBP12 gene (330 bp) was identified from our selection. If
this modification of the mRNA display procedure were adopted
for selection with cDNA libraries derived from other organs
such as liver and kidney, we believe that other FK506-binding
proteins might be discovered.
Because the affinity of the spartin-FK506 interaction
(Kd = 0.1 mM) is quite lower than that of the FK506-FKBP12 inter-Chemistry & Biology 20,action (0.4 nM), one may question whether this interaction is
physiologically relevant. Although further studies are needed,
the affinity of the known spartin-AIP4 interaction (Kd = 0.34 mM;
Hooper et al., 2010) is even lower than that of the spartin-
FK506 interaction, and thus, we believe that the endogenous
concentration of spartin is enough to bind to other molecules
with submicromolar affinity.
Spartin is related to neural disease and disorder. Two different
mutations (364_365 delAT or 1110 delA) that result in premature
truncation of the C-terminal region of spartin (Figure 2B) are
associated with hereditary spastic paraplegia (HSP), an inherited
neurologic disease characterized by paraparesis, spasticity, and
muscle wasting in the lower limbs (Bakowska et al., 2008;
Manzini et al., 2010; Patel et al., 2002). On the other hand, neuro-
toxicity, including disturbed consciousness, neuropathy, and
CNS damage, is a side effect of FK506 (Shou et al., 1998). Since
Brasaemle and colleagues reported that ADRP regulates the
turnover of lipid droplets and its expression level decreases as
adipocytes differentiate (Brasaemle et al., 1997), spartin is impli-
cated in regulation of the turnover of lipids through ADRP. Aber-
rant lipid droplet morphogenesis and lipid metabolism can
apparently lead to axonal damage. For example, seipin, one of
the HSP-associated proteins, like spartin, causes lipodystrophy
with abnormal lipid metabolism and is suggested to causemotor
neuron disease through the accumulation of lipids in motor neu-
rons (Agarwal and Garg, 2004). Additionally, abnormal lipid
metabolism affects the integrity of nervous system myelin
(Chrast et al., 2011). Furthermore, FK506 frequently induces
myopathy in kidney transplantation patients (Guis et al., 2003),
and lipid droplet-associated proteins such as PNPLA2 were re-
ported to induce myopathy in neutral lipid storage disease
(Fischer et al., 2007). These previous reports are not inconsistent
with the idea that FK506 induces at least some of its side effects,
including neurologic disorders and myopathy, by inducing
abnormal lipid metabolism as a result of modulating the protein
level of ADRP, although the precise mechanisms remain to be
fully established.SIGNIFICANCE
The identification of proteins that bind to a drug of interest is
likely to be an effective approach to elucidate potential side
effects and their mechanisms or unknown indications. In
this study, we used mRNA display to identify proteins as
binders to FK506, a potent immunosuppressant drug. We
identified a FK506-binding protein, spartin, which is related
to neural disease and disorder. We demonstrated that
FK506 binds to the C-terminal region of spartin and thereby
inhibits the interaction of spartin with TIP47, one of the lipid
droplet-associated proteins. We further confirmed that
FK506 inhibits colocalization of spartin and AIP4 in lipid
droplets, which increases the protein level of ADRP, a regu-
lator of lipid homeostasis. These results strongly suggest
that FK506 suppresses the proteasomal degradation of
ADRP, a substrate of AIP4, by blocking the localization of
AIP4 in lipid droplets. As shown in this study, mRNA display
is useful for the identification and characterization of drug-
protein interactions.935–942, July 25, 2013 ª2013 Elsevier Ltd All rights reserved 939
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mRNA Display Selection for FK506-Binding Proteins
Construction of the mRNA-displayed protein library was performed as previ-
ously described (Doi et al., 2007; Horisawa et al., 2004). Briefly, a human brain
cDNA library was amplified, transcribed, ligated with a PEG-puromycin
spacer, p(dCp)2-T(fluorescein)p-PEGp-(dCp)2-puromycin (Miyamoto-Sato
et al., 2003), and translated in a cell-free wheat germ translation system (Prom-
ega). The resulting mRNA-displayed protein library was added to FK506-im-
mobilized beads, mixed for 1 hr at 4C, washed five times, and then eluted
with proteinase K (Takara). The supernatant was purified and amplified with
RT-PCR. The RT-PCR product was separated by 2% agarose gel electropho-
resis. A fraction of the gel including DNA fragments longer than 400 bp was
packed with TAE buffer in seamless cellulose tubing (Eidia, Ibaraki, Japan)
and eluted by electrophoresis at 100 V for 2 hr. The extracted DNA was ampli-
fied, purified, and used for the next round selection. After several rounds of
selection, the RT-PCR product was cloned and sequenced. Details are pro-
vided in the Supplemental Experimental Procedures.
DNA Construction
The following plasmids and PCR products were prepared as described in the
Supplemental Experimental Procedures: pQBI25-SPG20 containing SPG20
gene and its deletion mutant pQBI25-SPG20DC; pcDNA3.1/Hygro()-HA-
SPG20 containing HA-tagged SPG20 gene and its deletion mutant
cDNA3.1/Hygro()-HA-SPG201110delA; the PCR product SP6-O29-FLAG-
SPG20-His-polyA containing FLAG-tagged SPG20 gene; pCR3.3TOPO-
SPG20 containing His6-tagged SPG20 gene; pCMV-tag2A-AIP4 containing
FLAG-tagged AIP4 gene; pcDNA3.1/Hygro()-TIP47-GST containing GST-
fused TIP47 gene; and the PCR product, SP6-O29-TIP47-GST-His-polyA.
Cell Lines
The human embryonic kidney cell line HEK293T (RIKEN Cell Bank, Ibaraki,
Japan, 2002) and human cervical cancer cell line HeLa (RIKEN Cell Bank, Ibar-
aki, Japan, 2002) were maintained in Dulbecco’s modified Eagle’s medium
(Nacalai Tesque, Kyoto, Japan) with 10% fetal bovine serum and 1% penicillin
and streptomycin.
Western Blotting
HeLa cells cultured to 80% confluence were treated with 0–100 mM FK506 for
1–48 hr. The cells were rinsed with PBS followed by lysis with RIPA buffer
(50 mM Tris-HCl, pH 7.6, 150 mMNaCl, 1 mM EDTA, 0.5% sodium deoxycho-
late, and 1% NP-40, 0.05% SDS) containing a protease inhibitor cocktail
(Nacalai Tesque) and a phosphatase inhibitor cocktail (Nacalai Tesque) so
that protein phosphorylation could be examined. For observation of the
ADRP expression level, HeLa cells were treated with 50 mg/ml cycloheximide
(Sigma, St. Louis, MO, USA) before treating with FK506. To examine the
expression level of spartin and AIP4, lysates were homogenized by sonication
for 10 min. Lysates were then centrifuged at 4C, 15,000 rpm for 15 min, and
the supernatant was removed. Protein concentrations were determined using
a BCA protein assay kit (Thermo, Rockford, IL, USA) and an equivalent amount
of protein was electrophoresed on 8% SDS-PAGE gel. Bands were detected
with primary antibodies against spartin (Santa Cruz, Santa Cruz, CA, USA),
HA-tag (Cell Signaling Technology, Beverly, MA, USA), FLAG-tag, b-actin,
GST (Sigma), AIP4, ADRP (Abcam, Cambridge, MA, USA) or TIP47 (Novus
Biologicals, Littleton, CO, USA), and HRP-conjugated secondary antibody
against rabbit or mouse (Millipore, Billerica, MA, USA). The blots were devel-
oped using ECL chemi-luminescence reagents (GE Healthcare, Waukesha,
WI, USA).
FK506-Spartin Binding Assay
HEK293T cells were transfected with plasmid pQBI25-SPG20 or pQBI25-
SPG20DC using Lipofectamine 2000 (Invitrogen). After 48 hr, these cells
were rinsed with PBS followed by lysis with lysis buffer (50 mM Tris-HCl, pH
7.6, 150 mM NaCl, 5 mM EDTA, and 0.1% Tween 20) containing the protease
inhibitor cocktail. The cell lysates were then centrifuged at 12,000 3 g for
20 min at 4C. The supernatant was mixed with 10% EtOH and added to
FK506-immobilized beads on a rotator for 1 hr at 4C. To perform the compet-
itive binding assay, 0–100 mM FK506 was added to the beads with EtOH and940 Chemistry & Biology 20, 935–942, July 25, 2013 ª2013 Elsevier Lthe supernatant. The beads were washed with lysis buffer containing 10%
EtOH, resuspended in SDS sample buffer (125 mM Tris-HCl, pH 6.8, 4%
sodium dodecylsulfate, 10% sucrose, and 0.01%bromophenol blue), and vor-
texed to elute bound molecules. The resulting eluate was separated with 8%
SDS-PAGE and the fluorescence of the GFP tag was detected with a Molec-
ular Imager FX (BioRad, Richmond, CA, USA). For endogenous spartin, cell
lysates from HeLa cells were used. The resulting eluate was separated with
8% SDS-PAGE and bands were detected with western blotting.
Surface Plasmon Resonance Analysis
HEK293T cells were transfected with plasmid pCR3.3TOPO-SPG20 using Lip-
ofectamine 2000. After 24 hr, these cells were rinsedwith PBS followed by lysis
with IPP150 (10mMTris-HCl, pH 8.0, 150mMNaCl, and 0.1%NP-40) contain-
ing the protease inhibitor cocktail. The cell lysates were then homogenized
with sonication followed by centrifugation at 12,000 3 g for 15 min at 4C.
The supernatant was removed and added to TALON Metal Affinity beads
(Nacalai Tesque) pre-equilibrated with IPP150 on a rotator for overnight at
4C. The resulting beads were washed with IPP150 containing 0 or 20 mM
imidazole and the protein was eluted with IPP150 containing 500 mM
imidazole.
The resulting eluates were further purified with gel filtration chromatography
with AKTA (GE Healthcare). We used the Superose 12 column (GE Healthcare)
and amixture of 0.1mg/ml blue dextran 2000, 0.35mg/ml albumin, 0.35mg/ml
ovalbumin, 0.35mg/ml chymotrypsin A, and 0.5 ribonuclease A as amolecular
weight marker.
Binding kinetics were determined with SPR analysis with a Biacore 3000 (GE
Healthcare). All experiments were performed at 25C using HBS-EP buffer.
Biotinylated FK506 was immobilized onto the SA sensor chip (GE Healthcare).
Themeasurements were performed under conditions of 388.5 resonance units
of the ligand and at a flow rate of 10 ml/min. To determine dissociation con-
stants, three different concentrations of purified spartin were injected. The
injection period for association was 350 s. After each measurement, the chip
surface was regenerated with 10 ml of Glycine 2.0 (GE Healthcare). The bind-
ing data were analyzed with the steady-state affinity model in the BIAevalua-
tion software ver. 4.1 (GE Healthcare).
ELISA
An FK506-immobilized plate was prepared by adding 1,200 nM biotinylated
FK506 in TBST (TBS with 0.1% Tween 20) to a Streptavidin C8 Transparent
plate (Nunc, Roskilde, Denmark) and shaking it for 1 hr at room temperature.
The plate was washed with TBST and nonspecific binding was blocked with
Block Buffer (DIG wash and block buffer set, Roche) by shaking for 1 hr at
room temperature. SP6-O29-T7-FLAG-spartin-His-polyA, SP6-O29-T7-
FLAG-FKBP12-His-polyA and SP6-O29-T7-CBPzz-polyA were transcribed
using RiboMax large-scale RNA production systems-SP6, and the transcrip-
tion product was purified with an RNeasy mini kit. The resulting mRNA was
translated in a cell-free wheat germ translation system. In vitro translated
T7-FLAG-spartin protein mixed with 0–100 mM FK506 or rapamycin (Sigma)
in TBST was added to the wells and the plate was shaken for 1 hr at room
temperature. It was washed with TBST, followed by incubation with HRP-con-
jugated antibody against FLAG-tag (Sigma) in TBST for 1 hr at room tempera-
ture. The plate was washed oncemore and the binding amount of each protein
was measured by using the ELISA POD substrate TMB kit (Nacalai Tesque)
with a SAFIRE microplate reader (Tecan, Mannendorf, Switzerland).
Similarly, SP6-O29-T7-FLAG-spartin-His-polyA and SP6-O29-FLAG-
TIP47-GST-His-polyA were transcribed using RiboMax large-scale RNA pro-
duction systems-SP6 and the transcription product was purified with an
RNeasy mini kit. The resulting mRNA was translated in a cell-free wheat
germ translation system. The TIP47-GST immobilized plate was prepared by
adding the in vitro translated TIP47-GST protein to a Glutathione F96 clear
plate (Nunc) and shaking it for 1 hr at room temperature. In vitro translated
T7-tagged spartin protein mixed with 0–100 mM FK506 in TBST was added
to the wells and the plate was shaken for 1 hr at room temperature. It was
washed with TBST, followed by incubation with HRP-conjugated antibody
against T7-tag (Novagen) in TBST for 1 hr at room temperature. The plate
was washed once more, and the binding amount of each protein was
measured by using the ELISA POD substrate TMB kit with a SAFIRE micro-
plate reader.td All rights reserved
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HeLa cells cultured to 80% confluence on poly-L-lysine-coated cover gla-
sses (Matsunami Glass, Osaka, Japan) were transfected with plasmids
pcDNA3.1/Hygro()-HA-spartin and pCMV-tag2A-AIP4 using the GeneJuice
Transfection Reagent. After 24 hr, the transfected cells were treated with
500 mM oleic acid (Nacalai Tesque) and 1 mM FK506 for 1 hr. These cells
were then fixed with 4% paraformaldehyde for 20 min followed by permeabi-
lization with 0.1% saponin (Nacalai Tesque) for 10 min. The sample was
stained with antibody against the HA tag and AIP4, followed by CF640R-con-
jugated anti-mouse IgG (Biotium, Hayward, CA, USA) and Alexa568-conju-
gated anti-rabbit IgG (Invitrogen). Lipids were stained with BODIPY493/503
(Invitrogen). Photobleaching was prevented by using the Slow Fade gold anti-
fade reagent with DAPI (Invitrogen).
Coimmunoprecipitation
The cell lysates from HEK293T cells transfected with pcDNA3.1/Hygro()-HA-
SPG20 and pCMV-tag2A-AIP4 was added to anti-FLAG M2 agarose beads
(Nacalai Tesque) that had been pre-equilibrated with lysis buffer three times
for 2 hr on a rotator at 4C. The resulting beads were washed with lysis buffer
three times and resuspended in SDS sample buffer containing 2% b-mercap-
toethanol, followed by heating for 10 min at 95C to denature proteins. The su-
pernatant was separated by 8% SDS-PAGE and analyzed with western
blotting.
GST Pull-Down Assays
HEK293T cells were transfected with plasmids pcDNA3.1/Hygro()-HA-spar-
tin and pcDNA3.1/Hygro()-TIP47-GST using the GeneJuice Transfection
Reagent. After 48 hr, the transfected cells were rinsed with PBS and lysed
with GST lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA,
1% Triton X-100, and 5% glycerol) followed by centrifugation at 12,000 3 g
for 15 min at 4C, and then the supernatant was collected. The supernatant
was mixed with 0–20 mM FK506 followed by incubation with Glutathione
Sepharose 4B (GE Healthcare) that had been pre-equilibrated with GST
wash buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, and 0.1%
Triton X-100). The resulting beads were washed three times with GST wash
buffer and resuspended in SDS sample buffer containing 2% b-mercaptoetha-
nol, followed by heating for 10min at 95C. The resulting eluate was separated
by 8% SDS-PAGE and analyzed with western blotting.
RT-PCR Analysis
Details are provided in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and can be found with this article online at http://dx.doi.org/10.1016/j.
chembiol.2013.05.011.
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